Evidence map›Paper›PMID 39793270›Full record

ArticleThe International journal on drug policy2025

The relationship of medical and recreational cannabis laws with opioid misuse and opioid use disorder in the USA: Does it depend on prior history of cannabis use?

Silvia S Martins, Emilie Bruzelius, Christine M Mauro, Julian Santaella-Tenorio, Anne E Boustead, Katherine Wheeler-Martin, Hillary Samples, Deborah S Hasin, David S Fink, Kara E Rudolph and 3 more

Abstract read
In one paragraph

Article in The International journal on drug policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Silvia S MartinsDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA. Electronic address: ssm2183@columbia.edu.
Emilie BruzeliusDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.
Christine M MauroDepartment of Biostatistics, Columbia University Mailman School of Public Health, New York, NY, USA.
Julian Santaella-TenorioNYU Grossman School of Medicine Department of Population Health, New York, NY, USA.
Anne E BousteadSchool of Government and Public Policy, University of Arizona, Tucson, AZ, USA.
Katherine Wheeler-MartinNYU Grossman School of Medicine Department of Population Health, New York, NY, USA.
Hillary SamplesRutgers University, New Brunswick, NJ, USA.
Deborah S HasinDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA; Columbia University Department of Psychiatry, New York, NY, USA.
David S FinkNew York State Psychiatric Institute, New York, NY, USA.
Kara E RudolphDepartment of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.
Stephen CrystalRutgers University, New Brunswick, NJ, USA.
Corey S DavisNYU Grossman School of Medicine Department of Population Health, New York, NY, USA; Network for Public Health Law, Edina, MN, USA.
Magdalena CerdáNYU Grossman School of Medicine Department of Population Health, New York, NY, USA.

Funding

Substance Abuse Epidemiology Training Program (SAETP) at Columbia UniversityT32DA031099 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DEBORAH S HASIN, Silvia Saboia Martins · 2012 to 2026
$6.1M
Examining the Synergistic Effects of Cannabis and Prescription Opioid Policies on Chronic Pain, Opioid Prescribing, and Opioid OverdoseR01DA045872 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CERDA, MAGDALENA, MARTINS, SILVIA SABOIA · 2019 to 2023
$4.3M
Multi-level associations between opioid use and overdose: Individual, clinical, and population-based risk factors for fatalityK01DA049950 · NIDA · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI SAMPLES, HILLARY · 2020 to 2024
$981k
COVID-19 Pandemic: Natural Experiment in Telehealth on Buprenorphine Treatment in a Large Integrated Healthcare SystemR00DA055724 · NIDA · YALE UNIVERSITY · PI David Stanley Fink · 2025 to 2026
$497k
COVID-19 Pandemic: Natural Experiment in Telehealth on Buprenorphine Treatment in a Large Integrated Healthcare SystemK99DA055724 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI FINK, DAVID STANLEY · 2023 to 2023
$174k
NIDA NIH HHS K01 DA049950NIDA NIH HHS K99 DA055724NIDA NIH HHS R00 DA055724NIDA NIH HHS R01 DA045872NIDA NIH HHS T32 DA031099
6 · The paper itself

Abstract

backgroundWider availability of cannabis through medical and recreational legalization (MCL alone and RCL+MCL) has been hypothesized to contribute to reductions in opioid use, misuse, and related harms. We examined whether state adoption of cannabis laws was associated with changes in opioid outcomes overall and stratified by cannabis use.

methodsUsing National Survey on Drug Use and Health (NSDUH) data from 2015 to 2019, we estimated cannabis law associations with opioid (prescription opioid misuse and/or heroin use) misuse and use disorder. All logistic regression models (overall models and models stratified by cannabis use), included year and state fixed effects, individual level covariates, and opioid-related state policies. Stratified analyses were restricted to individuals who reported lifetime cannabis use prior to law adoption to reduce potential for collider bias. Estimates accounted for multiple comparisons using false discovery rate (FDR) corrections and sensitivity to unmeasured confounding using e-values.

resultsOverall, MCL and RCL adoption were not associated with changes in the odds of any opioid outcome. After restricting to respondents reporting past-year cannabis use, we observed decreased odds of past year opioid misuse (adjusted odds ratio [AOR]: 0.57 [95 % confidence interval [CI]: 0.38, 0.85]; FDR p-value: 0.07), among individuals in states with MCL compared to those in states without cannabis laws. RCLs were not associated with changes in the odds of any opioid outcome beyond MCL adoption.

conclusionComparing individuals in MCL alone states to those in states without such laws, we found an inconsistent pattern of decreased odds of opioid outcomes, which were more pronounced among people reporting cannabis use. The pattern did not hold for individuals in RCL states. In line with a substitution-oriented perspective, findings suggests that MCLs may be associated with reductions in opioid use among people using cannabis but additional work to replicate and expand on these findings is needed.

Indexed as

Legislation, DrugMarijuana UseMedical MarijuanaOpioid-Related DisordersPrescription Drug MisuseAdolescentAdultAnalgesics, OpioidFemaleHealth SurveysHumansMaleMiddle AgedUnited StatesYoung AdultAnalgesics, OpioidMedical MarijuanaHeroinMedical cannabis lawsOpioid misuseOpioid use disorderPrescription opioidsRecreational cannabis laws

Identifiers

PMID39793270
PMCPMC11821435

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.